Longitudinal Changes in Physical Performance with Metabolic Dysfunction-Associated Steatotic Liver Disease and Coronary Artery Disease
Experimental and Clinical Endocrinology & Diabetes · 10.11.2026
DOI: 10.1055/a-3000-2942 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, erschienen am 10.11.2026. Verfasst von Jeonghoon Ha und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Catholic University of Korea Seoul St Mary's Hospital, Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul, Korea (t…. Gefördert von: Research of Korea Centers for Disease Control and Prevention.
Abstract (Originalsprache)
Background
Physical performance provides valuable insights into metabolic and cardiovascular health, particularly regarding metabolic dysfunction-associated steatotic liver disease (MASLD) and coronary artery disease (CAD).
Objective
This study examined the relationship between longitudinal changes in physical performance, assessed using the Timed Up and Go (TUG) test, and indicators of MASLD, CAD, and body fat distribution over time.
Methods
This 3-year longitudinal prospective cohort study included 1,096 older adults. Participants underwent baseline and follow-up assessments. Based on TUG results, participants were categorized into four groups: Normal→Normal (Group 1), Impaired→Normal (Group 2), Normal→Impaired (Group 3), and Impaired→Impaired (Group 4). MASLD indicators (Fibrosis-4 index [FIB-4], MASLD liver fat score, and hepatic steatosis index [HSI]), CAD indicators (coronary artery calcium [CAC] and coronary artery volume [CAV] scores), and body fat distribution (L3 cross-sectional visceral fat area [L3VFA], L3 cross-sectional subcutaneous fat area [L3SFA], and visceral-to-subcutaneous fat ratio [VSR]) were also analyzed.
Results
At baseline, groups with impaired TUG exhibited worse MASLD, CAD, and fat distribution profiles. Longitudinally, within-group analyses revealed distinct trajectories based on TUG changes over 3 years. For MASLD, the FIB-4 index significantly increased in participants whose TUG declined from normal to impaired (Group 3) or remained persistently impaired (Group 4)(p
Autor:innen und Institutionen
- The Catholic University of Korea Seoul St Mary's Hospital, Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul, Korea (the Republic of), Seocho-gu.
- Stanford University School of Medicine, Division of Endocrinology, California, United States, Stanford.
- Yonsei University College of Medicine, Division of Geriatrics, Department of Internal Medicine,, Seoul, Korea (the Republic of), Seodaemun-gu.
- Yonsei University College of Medicine, Division of Geriatrics, Department of Internal Medicine, Seoul, Korea (the Republic of), Seodaemun-gu.
- Yonsei University College of Medicine, Metabolism-Dementia Institute, Seoul, Korea (the Republic of), Seodaemun-gu.
- The Catholic University of Korea College of Medicine, Department of Preventive Medicine, Seoul, Korea (the Republic of), Seocho-gu.
ORCID-Profile: Hun-Sung Kim
Förderung
- Research of Korea Centers for Disease Control and Prevention
Zitieren
APA
Ha, J., Kim, K. J., Park, Y. S., Yim, H. W., Kim, H. S., & Kim, C. O. (2026). Longitudinal Changes in Physical Performance with Metabolic Dysfunction-Associated Steatotic Liver Disease and Coronary Artery Disease. Experimental and Clinical Endocrinology & Diabetes. https://doi.org/10.1055/a-3000-2942
Vancouver
Ha J, Kim KJ, Park YS, Yim HW, Kim HS, Kim CO. Longitudinal Changes in Physical Performance with Metabolic Dysfunction-Associated Steatotic Liver Disease and Coronary Artery Disease. Experimental and Clinical Endocrinology & Diabetes. 2026. doi:10.1055/a-3000-2942
BibTeX
@article{Ha2026,
author = {Ha, Jeonghoon and Kim, Kwang Joon and Park, Yang Sun and Yim, Hyeon Woo and Kim, Hun-Sung and Kim, Chang Oh},
title = {Longitudinal Changes in Physical Performance with Metabolic Dysfunction-Associated Steatotic Liver Disease and Coronary Artery Disease},
journal = {Experimental and Clinical Endocrinology & Diabetes},
year = {2026},
doi = {10.1055/a-3000-2942}
}
EUVIMED